On October 8, China signed an agreement with the Global Alliance for Vaccines and Immunization to formally join the “New Coronary Pneumonia Vaccine Implementation Plan.” This is an important measure for China to uphold the concept of the human health community and fulfill its commitment to promote vaccines as a global public product.
According to CCTV reports, after China’s vaccine research and development is completed and put into use. It will be a global public product and will be given priority to developing countries.
Wu Guizhen, the chief biosafety expert of the Chinese Center for Disease Control and Prevention, said that so far vaccines from four companies in China have entered Phase III clinical trials, and some have reached the end of Phase III. This means that in China, high-risk groups may soon be able to use such vaccines.
It is reported that regarding the COVID-19 vaccine, China has successively deployed 5 technical routes including inactivated vaccines, recombinant protein vaccines, and adenovirus vector vaccines for parallel development.
Currently, there are four vaccines that have entered Phase III clinical trials, including three inactivated vaccines and one adenovirus vector vaccine.
According to experts, China’s COVID-19 vaccine is expected to be put on the market by the end of this year.
